Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance
Osteoporosis International · 2026-10 · 37 (10) · 2763-2764
DOI: 10.1007/s00198-026-08234-9 ↗Kurz gefasst
Leserbrief in der Zeitschrift Osteoporosis International, online erschienen am 24.09.2026. Verfasst von Mehmet Serkan Kılıçoğlu. Beteiligte Einrichtung: Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Bezmialem Vakif University, 34093, Fatih, Istanbul, Türkiye. dr.serkan.kilic…. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Bezmialem Vakif University, 34093, Fatih, Istanbul, Türkiye. dr.serkan.kilicoglu@gmail.com.
Zitieren
APA
Kılıçoğlu, M. S. (2026). Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance. Osteoporosis International, 37(10), 2763-2764. https://doi.org/10.1007/s00198-026-08234-9
Vancouver
Kılıçoğlu MS. Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance. Osteoporosis International. 2026;37(10):2763-2764. doi:10.1007/s00198-026-08234-9
BibTeX
@article{Klolu2026,
author = {Kılıçoğlu, Mehmet Serkan},
title = {Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance},
journal = {Osteoporosis International},
year = {2026},
volume = {37},
number = {10},
pages = {2763--2764},
doi = {10.1007/s00198-026-08234-9}
}
EUVIMED